Prevalence and Predictors of Missed Dysplasia on Index Barrett’s Esophagus Diagnosing Endoscopy in a Veteran Population

• DOI: 10.1016/j.cgh.2021.04.008
• Publication Date: 2021-04-08T17:04:45Z
• Authors: Theresa H. Nguyen; Aaron P. Thrift; Rollin George; Daniel G. Rosen; Hashem B. El-Serag; Gyanprakash A. Ke...
• Keywords: Gastrointestinal; Medical Sciences; esophageal adenocarcinoma; Esophageal Neoplasms; Digestive System Diseases; Biophysics; 610; Diseases; Barrett’s esophagus; Adenocarcinoma; Biochemistry; Endoscopy, Gastrointestinal; Barrett Esophagus; 03 medical and health sciences; 0302 clinical medicine; missed dysplasia; Medical Specialties; Medicine and Health Sciences; Prevalence; risk factors; Humans; Biology; Retrospective Studies; Veterans; Hepatology; Gastroenterology; Life Sciences; Endoscopy; 3. Good health; incidence; and Structural Biology; Disease Progression; dysplasia rate

Limitations of endoscopic sampling may result in missed dysplasia at the diagnosis of Barrett's esophagus (BE). However, the role of close follow-up endoscopy is unclear. The aim was to evaluate the proportion of patients diagnosed with "missed" dysplasia within 18 months of their index nondysplastic BE (NDBE) diagnosis.This was a retrospective analysis of a cohort of BE patients diagnosed during 1990-2019 at the Houston VA. Patients with BE on index esophagogastroduodenoscopy (EGD) were classified as NDBE, indefinite dysplasia, or dysplastic (low- or high-grade dysplasia) based on initial biopsies. We identified NDBE patients who had follow-up EGD within 3-18 months after index EGD. We used logistic regression models to estimate odds ratios and 95% confidence intervals for risk factors of dysplasia on follow-up EGD.We identified 614 patients who had BE on index EGD. Among those with NDBE and follow-up EGD within 3-18 months (n = 271), 4.1% had definite dysplasia on follow-up, and an additional 14.0% had indefinite dysplasia. Proportions of definite or indefinite dysplasia at follow-up within 3-18 months significantly decreased from 32.6% among patients with index EGD before 2009 to 11.7% among patients with index EGD after 2013 (P for trend = .068). Those with any indefinite or definite dysplastic BE at follow-up within 3-18 months after index EGD (n = 49) were more likely to have BE length ≥3 cm on index EGD (odds ratio, 3.39; 95% confidence interval, 1.63-7.08) than those with persistent NDBE or no BE on follow-up.The occurrence of missed dysplasia on an index EGD has decreased over time. However, those with long segment BE were more than 3 times as likely to have missed dysplasia, and this group could benefit from dysplasia surveillance within 18 months of BE diagnosis.